Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the clinical efficacy of IPH1101 (with low-dose IL 2, as aldesleukin), administered in combination with a standard course of rituximab, in patients with Follicular Lymphoma having relapsed after at least one prior rituximab-containing line.
Critère d'inclusion
- Follicular lymphoma